Briefing
Ultrasensitive ctDNA Assay Lowers the Detection Floor in Esophageal Cancer
This commentary discusses an ultrasensitive MAESTRO analysis of 331 plasma samples from 36 patients with esophageal cancer treated with curative intent. It reports that 60% of ctDNA-positive samples were below 100 parts per million, and that every recurrence was preceded by postoperative ctDNA detection. These figures are quoted from the commentary's account of the underlying article.
- Design: Evidence level 3
- Assay: Not named in the abstract
Clinical Cancer ResearchPubMed 42975193DOI 10.1158/1078-0432.CCR-26-3052